Novo Nordisk has announced a strategic partnership with OpenAI that it hopes will place the company at the forefront of AI transformation in healthcare and help it bring new and better treatment options to patients faster. The partnership will apply advanced AI capabilities to analyse complex datasets, identify promising drug candidates, and reduce the time […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!